文献速递甲状腺疾病

转移性分化型甲状腺癌的最佳累积碘-131活度:平衡疗效与不良事件

Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

该研究回顾了1967至2019年671例转移性分化型甲状腺癌成人患者,按累积碘-131活度分为≤600 mCi、>600-1000 mCi和>1000 mCi三组,中位随访122个月。结果显示>A组10年生存率分别为72%、42.7%和29%,不良事件发生率分别为1.1%、5.7%和13.2%。作者认为累积活度至多1000 mCi可在保持低不良事件与获益于部分广泛转移且碘-131浓聚强烈患者之间取得有利平衡。

要点

  • 累积碘-131活度≤600、>600-1000、>1000 mCi三组10年生存率分别为72%、42.7%、29%。
  • 三组不良事件发生率分别为1.1%、5.7%、13.2%,>1000 mCi与骨髓抑制、肺功能下降及口干显著增加相关(P < .001)。
  • 作者认为累积活度至多1000 mCi可在低不良事件与获益于部分广泛转移且碘-131浓聚强烈患者之间取得有利平衡。

核心结论

  • 作者认为累积碘-131活度至多1000 mCi可在保持低不良事件与获益于部分广泛转移且碘-131浓聚强烈患者之间取得有利平衡。

研究设计与样本

  • 回顾性分析1967至2019年接受碘-131治疗并随访至少2年的转移性分化型甲状腺癌患者数据。
  • 共纳入671例成人患者,平均年龄48岁(范围19-81岁),中位随访122个月(四分位距82-180)。
  • 按累积活度分为A组(≤600 mCi)269例(40.0%)、B组(>600-1000 mCi)212例(31.6%)、C组(>1000 mCi)190例(28.4%)。

主要发现

  • A、B、C三组10年生存率分别为72%、42.7%、29%。
  • 共观察到40/671例(6%)不良事件,发生于38例患者:A组3例(1.1%)、B组12例(5.7%)、C组25例(13.2%)。
  • 5例发生第二原发恶性肿瘤:A组3例,B组和C组各1例。
  • 累积碘-131活度>1000 mCi与骨髓抑制、肺功能下降及口干显著增加相关(P < .001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal cumulative activity (CA) of I-131 therapy for patients with metastatic differentiated thyroid cancer (mDTC) remains contentious. This study aimed to determine the maximum CA of I-131 that could be administered without a significant increase in adverse events (AEs) by analyzing a long-term cohort of patients. METHODS: Data from patients with mDTC treated with I-131 therapy and followed for at least 2 years from 1967 to 2019 were reviewed. Patients were categorized into 3 groups based on the received CA: group A (≤600 mCi), group B (>600-1000 mCi), and group C (>1000 mCi). The study assessed long-term AEs and survival outcomes. RESULTS: The study included 671 adult patients with mDTC (mean age, 48 years; range, 19-81) with a median follow-up of 122 months (interquartile range: 82-180). Group A, group B, and group C comprised 269 (40.0%), 212 (31.6%), and 190 (28.4%) patients, respectively. Ten-year survival rates were 72%, 42.7%, and 29% in groups A, B, and C, respectively. A total of 40/671 (6%) AEs were observed in 38 patients: 3 (1.1%), 12 (5.7%), and 25 (13.2%) in groups A, B, and C, respectively. Five patients developed second primary malignancy: 3 in group A and 1 each in group B and C. However, CA >1000 mCi of I-131 was associated with significant increase in bone marrow suppression, decreased pulmonary function, and xerostomia (P < .001). CONCLUSION: The study suggests that a maximum CA of up to 1000 mCi strikes a favorable balance between keeping AEs low and benefiting a subset of patients with extensive metastases showing intense I-131 concentration.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bharadwaj MS, Ballal S, Bal C, et al. Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events. J Clin Endocrinol Metab. 2024. PMID: 38214553. doi:10.1210/clinem/dgae024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。